Jeil Pharma Holdings: Q1 2026 Results, Dividend Increase, and Share Buyback Plan

Consolidated Q1 2026: Revenue 150.4B KRW, Operating Profit 3.6B KRW, Net Income (controlling) 1.1B KRW (YoY decrease)
Dividend per share raised to 70 won (from 50 won, +40%), total dividend 1.1B KRW
On 2026.03.13, board approved a short-term plan for treasury share acquisition/disposal/cancellation (specific amounts undisclosed)
Net debt ratio improved to 72.7% (from 74.9% at year-end)
One pending lawsuit (claim amount 2.77B KRW, partial provision)
Subsidiary Onconic Therapeutics maintains tech export deals for Zastaprazan (JP-1366) to China, India, and Latin America